This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    NCT00202865
Previous Study | Return to List | Next Study

Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352) (CANDLE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00202865
First received: September 16, 2005
Last updated: March 22, 2017
Last verified: March 2017
  Purpose
This is a randomized, double-blind, multi-center, placebo-controlled study with two parallel treatment groups (placebo and infliximab) in subjects with ankylosing spondylitis (AS) to evaluate the efficacy of infliximab 3 mg/kg.

Condition Intervention Phase
Spondylitis, Ankylosing Biological: infliximab Biological: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: CANaDian Evaluation of Low DosE Infliximab in Ankylosing Spondylitis

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • The proportion of AS assessment responders ASAS20 (ie, a minimum 20% improvement from Baseline according to the ASAS response criteria) at Week 12. [ Time Frame: Week 12 ]

Secondary Outcome Measures:
  • Change from Baseline in the magnetic resonance imaging activity score at Week 12. [ Time Frame: Week 12 ]
  • Change from Baseline in BASFI at Week 12 and Week 50. [ Time Frame: Week 12 and Week 50 ]
  • Change from Baseline in BASDAI at Week 12 and Week 50. [ Time Frame: Week 12 and Week 50 ]
  • Change from Baseline in BASGI at Week 12 and Week 50. [ Time Frame: Week 12 and Week 50 ]
  • Change from Baseline in spinal mobility (BASMI) at Week 12 and Week 50. [ Time Frame: Week 12 and Week 50 ]
  • Change from Baseline in spinal mobility (EDASMI) at Week 12 and Week 50. [ Time Frame: Week 12 and Week 50 ]
  • Proportion of subjects achieving an ASAS40 at Week 12 and Week 50. [ Time Frame: Week 12 and Week 50 ]
  • Proportion of subjects achieving an ASAS50 at Week 12 and Week 50. [ Time Frame: Week 12 and Week 50 ]
  • Proportion of subjects achieving an ASAS70 at Week 12 and Week 50. [ Time Frame: Week 12 and Week 50 ]
  • Change from Baseline in the physical component of the SF-36 at Week 12 and Week 50. [ Time Frame: Week 12 and Week 50 ]
  • Assess the treatment survival. [ Time Frame: From baseline to week 50 ]
  • Quantify the number of subjects requiring dose titration. [ Time Frame: Week 22 and 38 ]
  • Assess predictors of response. [ Time Frame: Week 12 and 50 ]
  • Assess predictors of toxicity. [ Time Frame: 50 weeks ]

Enrollment: 76
Actual Study Start Date: May 1, 2005
Study Completion Date: May 1, 2007
Primary Completion Date: May 1, 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Biological: infliximab
Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
Other Names:
  • Remicade
  • SCH 215596
Placebo Comparator: 2 Biological: Placebo
Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Are men or women >=18 years of age at Screening.
  • Female subjects of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active during the study) must be using an acceptable method of birth control (eg, hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (eg, hysterectomy or tubal ligation), and must continue such precautions for 6 months after receiving the last study agent infusion, and have a negative serum pregnancy test prior to enrollment. Additionally, male subjects who are sexually active, with women of childbearing potential, should ensure that they or their partners are using adequate contraception
  • Have had a diagnosis of AS according to the modified 1984 New York criteria, prior to Screening.
  • Have active disease, as evidenced by a BASDAI score of >=4 at Baseline and at Screening
  • Screening tests must meet the following criteria:

    • Hemoglobin: >=9.0 g/dL (5.6 mmol/L) for men and >=8.5 g/dL (5.3 mmol/L) for women
    • Serum transaminase levels must be within 3 times the ULN
    • Serum creatinine <=1.4 mg/dL (107umol/L).
  • Are capable of reading and understanding subject assessment forms and providing written informed consent.
  • Have had a documented negative reaction to a PPD skin test (PPD induration < 5 mm) performed within 1 month prior to the first study infusion. If PPD negative, chest x-ray still required.
  • Subjects must understand English or French.

Exclusion Criteria:

  • Have had a serious infection (eg, sepsis, hepatitis, abscesses, pneumonia, or pyelonephritis), have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 8 weeks prior to randomization. Less serious infections (eg, acute upper respiratory tract infection, or simple urinary tract infection) need not be considered exclusions at the discretion of the investigator.
  • Have ever had a chronic or recurrent infectious disease including, but not limited to, chronic renal infection, chronic chest infection (eg, bronchiectasis), sinusitis, recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), open, draining, or infected skin wound, or ulcer.
  • Have ever had opportunistic infections (eg, herpes zoster (shingles), cytomegalovirus, pneumocystis carinii, aspergillosis, histoplasmosis)
  • Have had documented an atypical mycobacteria infection.
  • Have had active TB or recent close contact with an individual with active TB or ever had evidence of latent TB.
  • Have a chest radiograph (PA and lateral) that displays granulomas or apical fibronodular disease suggestive of previous TB as determined by the investigator.
  • Have documented Hepatitis B (surface antigen positive).
  • Have documented HIV.
  • Have a known malignancy or history of malignancy within 5-year period prior to Screening (with the exception of squamous or basal cell carcinoma of the skin that has been completely excised without evidence of recurrence). Have a history of lymphoproliferative disease including lymphoma, have multiple sclerosis, or other central demyelinating disorder, or have congestive heart failure.
  • Have a serious concomitant illness, other than the ones mentioned above, that might interfere with participation in the trial.
  • Have a known allergy to murine proteins or other chimeric proteins.
  • Have ever received any previous treatment with infliximab, etanercept or other anti-TNF agents prior to first study infusion.
  • Are pregnant, nursing, or planning pregnancy (both men and women) during the trial or within the 6-month period thereafter.
  • Have a contraindication to any study protocol component.
  • Subjects who have a contraindication to the MRI component of the study can be enrolled, however, they will be exempt from all MRI examinations.
  • Subjects with unstable doses of NSAIDS, DMARDs, analgesics or corticosteroids at Screening who will continue to receive these medications during the study.
  • Subjects who are receiving >10 mg of prednisone (or equivalent) daily.
  • Have a documented history of fibromyalgia confirmed by an appropriate physician specialist (ie, rheumatologist).
  • Have had a documented history of total ankylosis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Publications:
Study Data/Documents: CSR Synopsis  This link exits the ClinicalTrials.gov site

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00202865     History of Changes
Other Study ID Numbers: P04352
2472
Study First Received: September 16, 2005
Last Updated: March 22, 2017

Additional relevant MeSH terms:
Spondylitis
Spondylitis, Ankylosing
Bone Diseases, Infectious
Infection
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Joint Diseases
Arthritis
Infliximab
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on August 23, 2017